Journal article
Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK
- Abstract:
-
Summary: The venous thromboembolism risk among anti-osteoporotics is unknown. In this primary care study, the risk with other bisphosphonates [1.05 (0.94–1.18) and 0.96 (0.78–1.18)], strontium [0.90 (0.61–1.34) and 1.19 (0.82–1.74)], in the UK and Spain respectively, and denosumab [1.77 (0.25–12.66)] and teriparatide [1.27 (0.59–2.71)] in Spain, did not differ versus alendronate.
Introduction: Most of the known adverse drug reactions described for anti-osteoporosis medication (AOM)...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 222.1KB)
-
(Accepted manuscript, zip, 545.2KB)
-
- Publisher copy:
- 10.1007/s00198-017-4308-5
Authors
Bibliographic Details
- Publisher:
- Springer Verlag Publisher's website
- Journal:
- Osteoporosis International Journal website
- Volume:
- 29
- Issue:
- 2
- Pages:
- 467-478
- Publication date:
- 2017-12-03
- Acceptance date:
- 2017-11-06
- DOI:
- EISSN:
-
1433-2965
- ISSN:
-
0937-941X
- Pmid:
-
29199359
- Source identifiers:
-
809230
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:809230
- UUID:
-
uuid:29f0bf86-f1b6-40dc-af9b-43292de30a8f
- Local pid:
- pubs:809230
- Deposit date:
- 2018-01-03
Terms of use
- Copyright holder:
- International Osteoporosis Foundation and National Osteoporosis Foundation
- Copyright date:
- 2017
- Notes:
- © International Osteoporosis Foundation and National Osteoporosis Foundation 2017. This is the author accepted manuscript following peer review version of the article. The final version is available online from Springer Verlag at: 10.1007/s00198-017-4308-5
If you are the owner of this record, you can report an update to it here: Report update to this record